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Purpose/Objective: To identify which factors influence weight loss in 
patients undergoing radiotherapy.  
Materials and Methods: 74 patients were evaluated prospectively. 
Weight loss during radiotherapy and one month after treatment were 
analyzed. Parameters such as tumor stage, age, chemotherapy, tumor 
site and Eastern Cooperative Oncology Group score (ECOG) were 
analyzed to evaluate their influence in weight loss. All patients 
received supportive care with oral nutritional supplementation (ONS) 
and dietetic counseling. 
Results: There were 65 (79.8 %) men and 15 (20.2 %) female. Mean 
age was 62.5 years (range 39-85). Weight loss was evaluated weekly 
during radiotherapy and one month after treatment. A total of 46 
(65.7%) patients lost weight throughout radiotherapy, with a median 
weight loss during treatment of 4.73 kg (SD±3.91) which corresponds 
to a 6.55% (SD±4.84) net reduction from their baseline weight. One 
month after treatment, 45 (66.2%) patients had lost weight, with a 
median weight loss of 4.96 kg (SD±4.04), which corresponds to a 6.84% 
(SD±5.24) net reduction from their baseline weight. A total of 52 
patients (70.2 %) received chemotherapy. Median weight loss during 
treatment was 3.1 kg (SD±4.90) and 0.6kg (SD±3.49) respectively, for 
patients receiving chemotherapy and patients who did not (p = 0.068). 
Head and neck (HN) patients had a median weight loss of 3.3 kg, and 
the remaining patients had a weight loss of 0.6 kg (p=0.028). Stage III-
IVpatients lost more weight during radiation than stage I-II patients 
(p=0.005). No significant differences were found according to age. 
Multivariate analysis was performed to evaluate the association of 
these parameters with weight loss during radiotherapy. Head and neck 
tumor site (p<0.05) and the use of chemotherapy (p=0.011) were 
considered as independentrisk factors. When multivariate analysis was 
performed to evaluate the association of same variables with weight 
loss one month after treatment, the use of chemotherapy (p=0.009) 
and ECOG 2-3 (p=0.026) were considered as independent risk factors.  
Conclusions: Nutritional status and clinical parameters suchas tumor 
location (especially HN), chemotherapy and ECOG, should be 
evaluated prior to radiation therapy because these factors can 
influence weight loss during radiotherapy and also one month after 
treatment. Despite using ONS and dietary counseling patients lost 
weight during treatment. These findings further support the 
importance of weight control in patients undergoing radiotherapy. 
Future research evaluating the most effective nutritional intervention 
to avoid weight loss will help us optimizing the management of these 
patients. 
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Purpose/Objective: To evaluate the outcome of stereotactic re-
irradiation (SR-RT) for isolated local recurrent primary prostate 
cancer after external beam radiotherapy. 
Materials and Methods: Our experience started between May 2007 
and December 2009, in collaboration with CyberKnife Center CDI, 
Milan: 19 patients (with prostate or prostate bed recurrence in 15 and 
4 pts, respectively) were treated with CyberKnife (Accuray, 
Sunnyvale, CA)–based stereotactic radiotherapy (CBK-SRT), and these 
data have been recently published (B.A. Jereczek-Fossa Int. J. Rad. 
Oncol. Biol. Phys., Vol. 82, No. 2, pp. 889–897,2012). In all these 
patients, [11C]choline positron emission tomography/computed 
tomography (PET/CT) was performed. The median CBK-SRT dose was 
30 Gy in 5 fractions. Progression free survival rate at 30 months was 
25%. These promising preliminary results prompted us to continue the 
study at our Institution when, at the end of 2011, Advanced 
Radiotherapy Center ARC started. New machines dedicated to 
stereotactic radiotherapy and hypofractionated protocols have been 
implemented (CyberKnife and Vero).  
Results: Between March and September 2012 4 patients with locally 
recurrent prostate cancer have been treated with image guided SR-
RT. In all pts PET/CT and biopsy was performed before treatment. 
The total dose was 30 Gy in 5 fractions. Up till now, SR-RT was well 
tolerated (non acute events). Biochemical response was observed in 
all pts. 
Conclusions: SR-RT is a feasible approach for isolated local recurrent 
primary prostate cancer, offering excellent in-field tumor control and 
a low toxicity profile. Further investigation with a bigger number of 
pts is warranted to identify the patients who benefit most from this 
treatment modality  
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Purpose/Objective: Stereotactic lung tumor radiotherapy are 
frequently only one therapeutic option in non-small cell lung cancer 
patients without regional and distant metastases who are inoperable 
due to medical reasons or refuse surgery. In Centre of Oncology in 
Krakow SBRT protocol has been implemented in 2010. Aim of this 
study is to assess verification of set-up position before treatment and 
early results of the treatment. 
Materials and Methods: 26 previously untreated NSCLC patients were 
irradiated. Dose ranged from 24 to 60 Gy in 2-5 fractions (depended 
on dose constraints at organs at risk and tumor location). Patients 
were in supine position with his hands above head, immobilized using 
individual polystyrene-foam form. Planning was 4D computer 
tomography based. Irradiation was carried out on the accelerator with 
the verification of placement based on CBCT (Cone Beam CT). Shifts 
of the table were measured before each fraction. 
Results: The median follow-up period in patients undergoing radiation 
therapy was 9 months. Three tumor progression occurred after 
approximately 6 months (in two cases metastatic tumor, in one case 
tumor with central location). Local control rate was about 87%. 
Radiation tolerance was good, only one patient had shortness of 
breath, which subsided after the administration of steroids. Shifts in 
the X-axis table ranged from 0 to 15 millimeters (mean - 3.5 mm, 
median - 3 mm, SD - 3 mm, 83% of all shifts ranging from ±2mm of the 
measurements). The Y axis ranged from 0 to 10 millimeters (mean - 3 
mm, median - 3 mm, SD 2,3 mm, 99% of all shifts ranging from 
±2mm), and the Z-axis from 0 to 8 mm (mean - 2 mm, median -2.5 
mm, SD - 2.8 mm, 84% of all shifts ranging from ±2mm). 
Conclusions: Preliminary results of stereotactic radiation therapy of 
lung tumors are similar to the results reported by other authors. 
Consequently, the data relating to the accuracy of set-up was 
included in the updated treatment protocol.  
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Purpose/Objective: Resection is often the first option recommended 
for patients with smaller AVMs in noncritical areas of the brain; but 
some AVMs are inoperable due to their large size, eloquent location, 
deep venous drainage, and/or other anatomical considerations that 
are associated with unacceptably high rates of morbidity and 
mortality. Stereotactic radiosurgery (SRS) has been widely used to 
treat intracranial AVMs of complex anatomical location too. We 
reviewed our experience with radiosurgery of AVM with particular 
attention to clinical response and toxicity with different delivered 
dose. 
Materials and Methods: From January 2009 to November 2011, 22 
patients with diagnosis of AVM were treated at San Camillo Forlanini 
Radiotherapy department. Median age at SRS was 36,14 years (range 
11-63). 12 AVMs (54,5%) were located in brain left side with a 
prevalence involvement of the frontal lobe (5 left/2 right), parietal 
lobe (4 left/2 right), temporal lobe (3 left/2 right), occipital lobe (1 
left/2 right) and one sited in left cerebellum. We compared two 
groups of patients: in the first group (15 pts-68%) delivered dose was 
20 Gy with a median volume of 2.03 cc (0.1 – 6.7 cc); the latter group 
(7 pts-31,5%) received 16 Gy or less on a median volume of 8.97 cc 
